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Poster Session II S329the incidences of grade2-4 aGVHD (35.9% vs 31.6%, p 5 0.18)
and cGVHD (29.3% vs 30.5%, p 5 0.67). However, the liver in-
volvement of aGVHD was higher in recipients with HCV
(13.9% vs 23.9%, p 5 0.031), while there was no differences in
liver involvement of cGVHD (37.3% vs 45%, p 5 0.33) and
VOD (10.7% vs 17.3%, p 5 0.17). Furthermore, the recipients
with HCV had significantly higher non-relapse mortality (NRM;
25.9% vs 38.0% at 2 year, p\0.01) and poor overall survival
(OS; 51.4% vs 41.1% at 2 year, p\0.01). Multivariate analysis re-
vealed that HCV sero-positivity remained significant as a risk fac-
tor for NRM (HR 1.60, p\0.01) and OS (HR 1.34, p 5 0.016)
after adjusting with gender, age, disease, and donor source. Propor-
tions of patients who died due to hepatic failure (4.9% vs 14.3%)
and bacterial infection (9.4% vs 18.2%) were significantly higher
in recipients with HCV than in those without HCV.
Conclusion: HCV sero-positivity was identified as a risk factor for
poor survival in HSCT. In addition, we should carefully manage
not only liver dysfunction but also bacterial infection in HCV posi-
tive patients.336
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After allogeneic stem cell transplantation remaining recipient
dendritic cells (DCs) in secondary lymphoid organs are essential
to initiate acute graft-versus-host disease (aGVHD). Yet, to which
extend mucosal DCs in peripheral tissues contribute to augment,
maintain or even down-modulate aGVHD remains elusive. There-
fore, we investigated the function of host DCs during the effector
phase of intestinal aGVHD. Until day 8 after transplantation
(H-2q FVB/N into H-2b C57BL/6, 9Gy) we detected predomi-
nantly persisting host DCs but only few donor DCs by immunoflu-
orescence microscopy. Histopathological analysis revealed high
numbers of host DC - donor T cell contacts in the intestinal mu-
cosa during the aGVHD effector phase. Time kinetics experiments
established that these dominating population of CD11c+CD11b+
intestinal DCs arose from radiation-resistant host-type monocytes
that were attracted to areas of inflammation and differentiated
into DCs. At sites of T cell contact DCs engaged costimulatory
molecules such as CD80. To address the role of this interaction
we induced aGVHD in transgenic C57Bl/6-DOG mice that ex-
press the diphtheria toxin (DTx) receptor in DCs under the control
of the CD11c promoter and subsequently applied DTx intraperito-
neally to eliminate host type DCs. Immunofluorescence micros-
copy and FACS analysis proved efficient host DC depletion in
the intestinal tract (.90%). DC depleted DOG recipients pre-
sented considerably higher GVHD scores and reduced survival
than aGVHD controls that did not receive DTx (n 5 25/group).
Additional controls were used in order to rule out possible cyto-
toxic effects of the DTx: WT mice, syngeneic controls and bone
marrow controls sensitive to the toxin, were not affected by the ad-
ministration of DTx. Subsequently we excluded a possible reduc-
tion of FoxP3+ regulatory T cells in the intestinal tract from
DTx and non-DTx treated mice. Inflammatory cytokines such as
IFN-g and TNF did not differ in the serum of DTx and non-
DTx treated mice on day 6 after allo-HCT, ruling out a possible
cytokine storm effect due to the DC killing. However, elevated
levels of the inflammatory cytokine CCL2 in DTx treated DOG
mice indicate that DC depletion enhances signals to recruit precur-
sors in order to refill the mucosal DC-compartment. Our study
provides evidence for a likely underappreciated function of DCs
during later stages of aGVHD and provides evidence for a protec-
tive role of remaining host DCs from monocytic origin during
aGVHD.337
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Introduction: BK-virus induced hemorrhagic cystitis (HC) fre-
quently affects patients undergoing allogeneic hematopoietic stem
cell transplant (allo-HSCT) and results in significant morbidity
and mortality. There are no existing guidelines to dictate clinical
practice.We present our institutional data and recommend a clinical
practice guideline that could potentially improve the outcomes of
patients with BK-virus infections.
Methods: Our retrospective analysis included 75 consecutive pa-
tients who underwent allo-HSCT from 2001-2011. Data was col-
lected on patients with PCR proven BK-viuria under existing IRB
approved protocols.
Results: 12% of all patients developed PCR proven HC. The me-
dian age of patients at transplant was 37-yrs. 66% had AML or
ALL and the median number of prior therapies was 3. 33% had
a MUD transplant while 66% received RIC conditioning and 33%
received ATG. The mean CD34+ cell dose was 4.8x106/kg and the
CD3+ cell dose was 8.6x1011/kg. The median time of onset of HC
was 44-days and lasted for an average of 53-days. 33% patients
were neutropenic at the onset of HC and the mean absolute neutro-
phil count was 4300/ul. Most common symptoms were dysuria in
66%, bladder spasms in 44% and urinary retention in 22%. All pa-
tients had receivedGVHDprophylaxis withmethotrexate and tacro-
limus and 77% were on concurrent steroids and mycophenolate.
88% of patients had concurrent acute GVHD at the time of HC.
88% had CMV and 11% had EBV viremia at the time of HC.
44% developed BK-viremia while 55% had BK-virus induced ne-
phropathy defined as an increase of serum creatinine.1.5. Manage-
ment approach was tiered into prophylaxis, symptomatic relief and
anti-viral therapy. All patients received ciprofloxacin and 88% re-
ceived IVIg.No single therapy component including reduced immu-
nosuppression, cidofovir and leflunomide was independently
identified as a more efficacious option (p.0.05), but of the patients
who received cidofovir, 75% had resolution of symptoms and were
able to clear the BK-viuria.
Conclusion:Our analysis suggests that BK-virus induced HC is the
result of multifaceted host and donor interactions and the concurrent
use of immune altering therapies. We have also developed a multi-
tiered approach that includes prophylactic intervention for patients
undergoing T-cell depleting regimens; symptomatic management;
and antiviral therapy in select subsets of patients to uniformly man-
age our patients in an effort to improve clinical outcomes.338
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T cell alloreactivity against human CD34+ cells was tested for the
first time in-vivo in a NOD/SCID g-null (NSG) mouse model. Hu-
man allogeneic blood CD3+ T cells were co-transplanted with allo-
geneic cord blood CD34+ cells (2 x 105/mouse) in sublethally
irradiated mice at high (50:1, 10:1, 5:1) or low (2:1, 1:1, or 0.5:1)
CD3:CD34 cell ratio. Control mice received CD34+ cells alone.
At 6 weeks post transplant, marrow and spleen cells were harvested
and analyzed by flow cytometry. Independently of high or low
CD3:CD34 cell ratio of the graft, all the mice showed a reduced
overall number of huCD45+ cells in the marrow (p 5 0.0001) com-
pared to control. Stem cell graft failure was documented by detecting
only the engraftment of human T cells and no myeloid or B cells in
the marrow and spleen of mice at every T cell:CD34 ratio tested.
HuCD45+ T cells included CD4+ and CD8+ cells at normal ratio
and a low number of CD56+ cells. Failure to engraftment of
CD34+ cells was also confirmed by FISH analysis in animals
S330 Poster Session IItransplanted with sex-mismatch CD34+ and CD3+ cells. Only when
mice were transplanted with a very low CD3:CD34 cell ratio (0.1:1)
a mix chimerism of huCD45+ CD3+ (21611%) T cells, CD19+
(4469%) B cell, CD34+ cells (361%), CD33+ myeloid cells
(1461%) and CD14+ monocytes (661%) was observed. To investi-
gate whether a single T cell population could cause stem cell rejec-
tion, mice were transplanted with selected CD3+CD4+ or
CD3+CD8+ T cells and CD34+ cells at 1:1 ratio. Rejection was ob-
served in 100% of mice transplanted with human CD3+CD4+ cells.
CD4+ cells in marrow and spleen were mostly CD45RA+. Instead,
mice transplanted with human CD3+CD8+ cells showed a mixed
chimerism of T, B and myeloid cells both in marrow and spleen.
Spleen was larger in recipients of CD4+ than CD8+ cells (p 5
0.005). Finally, spleen cells obtained from mice transplanted with
CD4+ or CD8+ cells were tested in-vitro as responders against irra-
diated CD34+ cells in mixed leucocyte cultures. Controls included
CD4+ or CD8+ cells that were frozen at the time of transplant.
Spleen CD4+ cells and both CD4+ and CD8+ control cells prolifer-
ated after stimulation with CD34+ cells, whereas spleen CD8+ cells
were unresponsive in-vitro. These results show that alloreactive
CD4+ T cells serve an important role in stem cell rejection while
CD8+ T cells appear to facilitate immune tolerance. Our work
also supports the use of NSG mice to analyze the mechanisms of
stem cell rejection or graft failure.339
HEMATOPOIETIC CELL TRANSPLANTATION CO-MORBIDITY INDEX
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In recent decades, several advances were made in the management
of patients (pts) who underwent allogeneic hematopoietic stem cell
transplantation (HSCT). Tools that could predict TRM, based on
pre HSCT characteristics and co-morbidities were always sought.
Some of these tools are the modified hematopoietic cell transplanta-
tion co-morbidity index (HCT-CI).Our aim was to apply the
modified HCT-CI and correlated it with overall survival (OS) and
non-relapsemortality (NRM).This analysis include patients who un-
derwent an allogeneic HSCT, for malignant and non malignant he-
matological diseases, after high or low dose conditioning regimens,
from related and unrelated donor, from 1993 to 2010. Each co-mor-
bidity was assigned an integer weight, and theHCT-CI score was the
sum of this integer weights. The patients were then assigned to one
of the risk groups 0, 1, 2 and 3 ormore. Kaplan-Meier was applied for
estimation of overall survival. NRMwas estimated by cumulative in-
cidence considering primary relapse disease as competing risk.457
pts were analyzed at the beginning. However, 331 (72.4%) were
evaluable, 126 (27.6%) were excluded when at least one parameter
was missing. 208 (63%) were male with a median age of 36.5 (5-
65) years, 249 (75%) pts received high dose (HD) conditioning
and 82 (25%) low dose (LD). HCT-CI in HD was: 127 (51%) score
0; 39 (16%) score 1; 19 (7%) 2 and 64 (26%) score $ 3; in LD 33
(40%) score 0; 14 (17%) score 1; 8 (10%) score 2 and 27 (33%) score
$ 3. The median follow up in HD was 22 months (0-201) and 9 (0-
203) in LD.The adjustedOS at 10 year forHD conditioning accord-
ing to the HCT-CI was 55% for score 0, 34% for score 1-2 & 34%
for score$ 3 and for LD conditioning was 58% for score 0, 53% for
score 1-2 & 15% for score $ 3 (p\ 0.0001). The NRM rate in the
HD cohort was 32% in the pts with a score 0, 42% for score 1-2
and 53% in the score $ 3. In the LD cohort, the NRM was 23%
in the pts with a score of 0; 35% for score 1-2 and 54% in the score
$ 3 (p 5 0.002). The adjusted OS for conditioning type in patients
with cardiac valve disease was associated to a lower OS (29% and
33% p 5 0.002) whereas mild hepatic involvement was just signifi-
cant in the HD cohort. The OS and NRM were worse for score $
3 either in HD and LD groups. The heart valve disease emerged
as a worse outcome in both conditioning type and mild hepatic in-
volvement only in HD group. The HCT-CI showed to be a valid
tool to predict outcome after allogeneic HSCT.340
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Background: Mantle cell lymphoma (MCL) commonly has an ag-
gressive course and short survival with conventional chemotherapy.
Allogeneic stem cell transplantation (allo-HSCT) is a potentially cu-
rative treatment for a subset of MCL patients.
Methods:We conducted a retrospective analysis including 41 con-
secutive MCL patients who underwent allo-HSCT. Patients with
the blastic variant of MCL; extensive marrow involvement; multiple
relapses after conventional chemotherapy; relapse after autologous
stem cell transplantation (ASCT); unable to collect stem cells to un-
dergo ASCT were considered eligible for allo-HSCT.
Patients:Median age was 54 years (range: 32-70). Median time from
diagnosis to transplant was 18 months (range: 5.4-118). Disease sta-
tus at allo-HSCT included CR1 (n 5 7), induction failure (n 5 13),
1st relapse (n5 13);.1st relapse (n5 8). 31 patients (76%) had stage
IV disease at diagnosis. Median number of prior regimens was 3
(range: 1-7). 35 patients (85%) had chemosensitive disease. 25
patients received allo-HSCT from a matched sibling and 16 from
unrelated donors. Conditioning regimens were fludarabine/melpha-
lan-based (n5 29), or TBI-based (n5 12). Most (80%) received pe-
ripheral blood stem cells. 23 (56%) received tacrolimus and
sirolimus; 18 received cyclosporine or tacrolimus with methotrexate
(n 5 12) or cellcept (n 5 6) for GVHD prophylaxis.
Results: At a median follow-up of 1.7 years, 59% of the patients
were still alive. The estimated 5-year overall and progression free-
survival was 51% (95% CI, 31% - 68%) and 30% (95% CI, 14% -
48%), respectively.The 5-year cumulative incidence of relapse and/
or progression was 43% (95% CI, 26% - 63%). The incidence of
acute and chronic GVHD was 56% and 63%, respectively. The
1-year and 5-year non-relapse related mortality (NRM) was 15 %
(95% CI, 7% - 29%) and 27% (95% CI, 15% - 43%). Factors asso-
ciatedwith increased risk of death and/or disease relapse/progression
were: time from diagnosis to transplant, advanced disease status at
transplant and prior ASCT.Patients transplanted after one or more
relapse events were at 7.28 times the risk of failure compared to those
in first CR1 (95%CI: 0.94 - 56.5; p 5 0.06).
Conclusions:These results suggest that long-term disease control is
possible after allo-HSCT for a subset of patients with MCLwith ac-
ceptable toxicity. Allo-SCT during CR1may offer long-term disease
control in patients with blastoid variant or those unable to undergo
autologous SCT.341
ASSESSMENT OF LIVER FIBROSIS BY DIAGNOSTIC VALUE OF TRANSIENT
ELASTOGRAPHY (FibroScan) IN THE IN PATIENTS WITH b-THALASSE-
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Introduction: Transient elastography (TE) is a valuable non-inva-
sive method to assess liver fibrosis. The present study aimed to eval-
uate the diagnostic value of TE in the assessment of hepatic fibrosis
in patients with b-thalassemia major (TM) who are candidates for
hematopoietic stem cell transplantation.
Method:We prospectively assessed the results of TE in 41 b-thalas-
semia major patients (median age of 7 years; range 2.6-20 years;
65.9%male) who were candidates for hematopoietic stem cell trans-
plantation (HSCT) and compared these results with the histological
fibrosis stage from liver biopsies. The diagnostic values were com-
pared by calculating the area under the receiver operating character-
istic curves (AUROCs).
